A prophylaxis of rejection,
sirolimus is critical in treatment for chronic allograft dysfunction, and
refractory acute rejection. Besides, it is now also considered a powerful
immunosuppressant. And, this can be transformative as it is supposedly better
than available alternatives. The reason behind the claim is the absence of
nephrotoxicity which is inherent in most immunosuppressants. Besides, tit is as
efficient as cyclosporine. Experts claim that it offers both the cyclosporine
effect as well as the steroid sparing effect.
Additionally, it acts as an
antitumor, anti-fungal and as an anti-smooth muscle proliferative. As per a
recent study of the global sirolimus market dynamics,
Transparency Market Research (TMR) notes that the market will chart a CAGR
(Compound Annual Growth Rate) of 1.0% over the forecast period of 2019 – 2027.
This will contribute to growth in global sirolimus market worth, bringing it up
to a USD 304.08 million by 2027 from USD 285 million in 2018.
Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=66860
The global sirolimus market a very
fragmented landscape with a large number of players hustling hard. Some of the
known names operating the playfield include Pfizer, Inc., Biocon, Dr. Reddy’s
Laboratories Ltd., Concept Medical, Inc., Stentys SA, Torrent Pharmaceuticals
Ltd., Zydus Cadila, and Intas Pharmaceuticals Ltd, among others.
Players are dependent on a number
of strategies to grasp a bigger share of the growth pie. Some of these are new
and better product development, and product approvals. Others include mergers
and acquisitions and strategic partners and collaborations with players that
show great synergy, helping a better market penetration and a firmer hold on
the market share.
Rising Incidence of
Target Diseases Will Lead to Growth in Global Sirolimus Market over the
Forecast Period
A rise in preference for generic drugs is restraining the
global sirolimus market from reaching its full potential. But the factor that
is offsetting this impact is the rise in incidence of target diseases, a level
of chronic disease in the United States gives an insightful picture considering
it is one of the most advanced countries in terms of medical treatment.
Six in every ten people in the country have one chronic
disease and four in every ten have at least two. Going forward (in another 30
years) the region will also see a steep rise in geriatric population,
compounding the situation further. The ratio of people aged 65 and above will
be one in every four peoples. A similar ratio will be noted in Europe. The
robust reimbursement framework and an impressive healthcare infrastructure in
both the regions will support the growth of the sirolimus market.
Besides, there is a general rise in disposable income
that is adding to the growth if the global sirolimus market.
Also, as pharmaceutical companies take note, and a robust
pipeline comes into the spotlight, it good news for the market outlook.
More Trending Reports by Transparency
Market Research:
About Us
Transparency Market Research is a global market
intelligence company, providing global business information reports and
services. Our exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers. Our
experienced team of Analysts, Researchers, and Consultants, use proprietary data
sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised
by a team of research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability, Transparency Market
Research employs rigorous primary and secondary research techniques in
developing distinctive data sets and research material for business reports.
Contact
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
